Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2019, Vol. 10 Issue (5) : 1026-1036     DOI: 10.14336/AD.2018.1129
Orginal Article |
Characterization of Alzheimer’s Disease Using Ultra-high b-values Apparent Diffusion Coefficient and Diffusion Kurtosis Imaging
Yingnan Xue1, Zhenhua Zhang1, Caiyun Wen1, Huiru Liu1, Suyuan Wang1, Jiance Li1, Qichuan Zhuge2, Weijian Chen1,*, Qiong Ye1,*
1Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Download: PDF(862 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

The aim of the study is to investigate the diffusion characteristics of Alzheimer’s disease (AD) patients using an ultra-high b-values apparent diffusion coefficient (ADC_uh) and diffusion kurtosis imaging (DKI). A total of 31 AD patients and 20 healthy controls (HC) who underwent both MRI examination and clinical assessment were included in this study. Diffusion weighted imaging (DWI) was acquired with 14 b-values in the range of 0 and 5000 s/mm2. Diffusivity was analyzed in selected regions, including the amygdala (AMY), hippocampus (HIP), thalamus (THA), caudate (CAU), globus pallidus (GPA), lateral ventricles (LVe), white matter (WM) of the frontal lobe (FL), WM of the temporal lobe (TL), WM of the parietal lobe (PL) and centrum semiovale (CS). The mean, median, skewness and kurtosis of the conventional apparent diffusion coefficient (ADC), DKI (including two variables, Dapp and Kapp) and ADC_uh values were calculated for these selected regions. Compared to the HC group, the ADC values of AD group were significantly higher in the right HIP and right PL (WM), while the ADC_uh values of the AD group increased significantly in the WM of the bilateral TL and right CS. In the AD group, the Kapp values in the bilateral LVe, bilateral PL/left TL (WM) and right CS were lower than those in the HC group, while the Dapp value of the right PL (WM) increased. The ADC_uh value of the right TL was negatively correlated with MMSE (mean, r=-0.420, p=0.019). The ADC value and Dapp value have the same regions correlated with MMSE. Compared with the ADC_uh, combining ADC_uh and ADC parameters will result in a higher AUC (0.894, 95%CI=0.803-0.984, p=0.022). Comparing to ADC or DKI, ADC_uh has no significant difference in the detectability of AD, but ADC_uh can better reflect characteristic alternation in unconventional brain regions of AD patients.

Keywords Alzheimer’s Disease      Ultra-high B-values Apparent Diffusion Coefficient      Diffusion Kurtosis Imaging      Apparent Diffusion Coefficient      ADC_uh      DKI     
Corresponding Authors: Chen Weijian,Ye Qiong   
About author:

Jean-Marc Burgunder is currently a visiting professor at Sichuan University (Chengdu), Central South University (Changsha) and Sun Yat Sen University (Guangzhou) in China.

Just Accepted Date: 03 December 2018   Issue Date: 27 September 2019
E-mail this article
E-mail Alert
Articles by authors
Xue Yingnan
Zhang Zhenhua
Wen Caiyun
Liu Huiru
Wang Suyuan
Li Jiance
Zhuge Qichuan
Chen Weijian
Ye Qiong
Cite this article:   
Xue Yingnan,Zhang Zhenhua,Wen Caiyun, et al. Characterization of Alzheimer’s Disease Using Ultra-high b-values Apparent Diffusion Coefficient and Diffusion Kurtosis Imaging[J]. Aging and disease, 2019, 10(5): 1026-1036.
URL:     OR
Figure 1.  Selections of region of interest. (A, C) The selected ROIs on the vcDWI maps. (B, D) The ROIs were projected onto the ADC_uh maps. The yellow part is the ROI range. AMY, amygdala; HIP, hippocampus; THA, thalamus; CAU, caudate; GPA, globus pallidus; LVe, lateral ventricles; FL, frontal lobe (WM); TL, temporal lobe (WM); PL, parietal lobe (WM); CS, centrum semiovale.
Number (M/F)11/208/120.774*
Table 1  Demographic and cognitive characteristics of all participants.
Figure 2.  Receiver-operating characteristic curves (ROC) of classifications between AD and HC patients. ADC, ADC_uh, and DKI were separately assessed for differential diagnosis. Then, any combination of them was assessed separately. Finally, all of them was assessed together. Compared to ADC_uh, a higher AUC was obtained by combining ADC_uh values and ADC values (0.897, 95% CI=0.779-0.964, p=0.022). There was no significant difference between the other ROCs. The diagonal line represents a random classification performance.
Mean ± SDCVP-value
right HIP mean (×10-3mm/s)AD0.961±0.1260.1310.008
right HIP median (×10-3mm/s)AD0.956±0.1160.1220.001
left CAU skewnessAD0.053±0.55410.4840.013
right LVe skewnessAD0.377±0.8812.3380.000
left FL kurtosisAD2.888±0.6890.2390.036
right PL mean (×10-3mm/s)AD0.815±0.0910.1110.002
right PL median (×10-3mm/s)AD0.818±0.0940.1150.003
left THA mean (×10-3mm/s)AD0.358±0.0320.0890.047
left LVe kurtosisAD3.16±0.8000.2530.028
right TL mean (×10-3mm/s)AD0.274±0.0420.1540.033
right TL median (×10-3mm/s)AD0.273±0.0450.1650.032
left TL mean (×10-3mm/s)AD0.276±0.0390.1410.022
left TL median (×10-3mm/s)AD0.273±0.0380.1380.038
right CS mean (×10-3mm/s)AD0.273±0.0380.0880.021
right CS median (×10-3mm/s)AD0.214±0.0190.0890.016
Table 2  Comparisons of regional diffusion intensity in ADC or ADC_uh between AD and HC group.
left FL kurtosisAD3.020±0.7750.2570.030
right PL mean (×10-3mm/s)AD0.942±0.1050.1120.003
right PL median (×10-3mm/s)AD0.943±0.1070.1130.004
right THA medianAD0.713±0.0720.1010.046
right LVe meanAD0.266±0.0490.1850.042
left LVe meanAD0.263±0.0490.1870.004
left LVe medianAD0.279±0.0400.1430.006
right FL kurtosisAD5.950±3.1400.5730.009
left FL kurtosisAD5.750±3.0100.5240.019
left TL meanAD0.740±0.1060.1440.009
left TL medianAD0.754±0.1040.1380.018
right PL meanAD1.000±0.1390.1380.019
right PL medianAD0.994±0.1270.1280.015
left PL meanAD0.949±0.1460.1540.007
left PL medianAD0.940±0.1430.1520.010
right CS meanAD1.060±0.1130.1070.011
right CS medianAD1.040±0.1090.1050.004
Table 3  Comparisons of regional diffusion intensities in Dapp or Kapp between the AD and HC groups.
Figure 3.  Bland-Altman plots of reproducibility of MRI. Bland-Altman plots for ADC mean (A), ADC_uh mean (B), Dapp mean (C) and Kapp mean (D) show a low mean difference between the two tests (continuous line: mean difference, dashed lines: 95% confidence interval of the mean difference).
ADC left FL kurtosis550**0.001
ADC right PL mean-.368*0.042
ADC right PL median-.356*0.049
ADC_uh right TL mean-.420*0.019
ADC_uh right TL median-.386*0.032
Dapp left FL kurtosis.546**0.001
Dapp right PL mean-.416*0.020
Dapp right PL median-.403*0.024
Table 4  Correlations with MMSE score for all parameters.
AUC95% CI aPb
ADC0.8260.694 - 0.918NL
ADC_uh0.7660.627 - 0.8730.501
DKI0.8470.718 - 0.9320.728
ADC+ADC_uh0.897#0.779 - 0.9640.172
ADC+DKI0.8400.711 - 0.9280.729
ADC_uh+DKI0.8940.775 - 0.9620.284
ADC+ADC_uh+DKI0.8680.743 - 0.9460.416
Table 5  Comparison of receiver-operating characteristic (ROC) curves.
ADC mean0.7820.000**
ADC median0.7600.000**
ADC skewness0.1940.006*
ADC kurtosis0.2260.001*
ADC_uh mean0.9010.000**
ADC_uh median0.8970.000**
ADC_uh skewness0.1330.061
ADC_uh kurtosis0.0580.412
Dapp mean0.7100.000**
Dapp median0.6750.000**
Dapp skewness0.1690.017*
Dapp kurtosis0.1420.046*
Kapp mean0.9290.000**
Kapp median0.9340.000**
Kapp skewness0.1930.006*
Kapp kurtosis0.2780.000**
Table 6  The correlations of ADC, ADC_uh, Dapp and Kapp parameters between the two tests.
[1] Organization WH (2017). Global action plan on the public health response to dementia 2017-2025. Geneva: World Health Organization. 52 pp.
[2] Organization WH (2018). Towards a dementia plan: a WHO guide. Geneva: World Health Organization. 78 pp.
[3] Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984). Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science, 225:1168-1170.
[4] Wegmann S, Jung YJ, Chinnathambi S, Mandelkow EM, Mandelkow E, Muller DJ (2010). Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability. J Biol Chem, 285: 27302-27313.
[5] Braak H, Braak E (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol, 82:239-259.
[6] Kidd M (1963). Paired helical filaments in electron microscopy of Alzheimer's disease. Nature, 197:192-193.
[7] Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, 549:523-527.
[8] Vergallo A, Bun RS, Toschi N, Baldacci F, Zetterberg H, Blennow K, et al. (2018). Association of cerebrospinal fluid alpha-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimers Dement: [in press].
[9] Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med, 4:147ra111.
[10] Lei Y, Han H, Yuan F, Javeed A, Zhao Y (2017). The brain interstitial system: Anatomy, modeling, in vivo measurement, and applications. Prog Neurobiol, 157:230-246.
[11] DeVos SL, Corjuc BT, Oakley DH, Nobuhara CK, Bannon RN, Chase A, et al. (2018). Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. Front Neurosci, 12:267.
[12] Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, et al. (2018). Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest, 128:2144-2155.
[13] Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. (2016). Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain, 139:1551-1567.
[14] Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V, et al. (2018). Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron, 99:64-82.e67.
[15] Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, et al. (2015). beta-Amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1. Biogerontology, 16:85-98.
[16] Bourgade K, Dupuis G, Frost EH, Fulop T (2016). Anti-Viral Properties of Amyloid-beta Peptides. J Alzheimers Dis, 54:859-878.
[17] Bourgade K, Le Page A, Bocti C, Witkowski JM, Dupuis G, Frost EH, et al. (2016). Protective Effect of Amyloid-beta Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model. J Alzheimers Dis, 50:1227-1241.
[18] Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB (2007). Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett, 429:95-100.
[19] Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, et al. (2016). Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Sci Transl Med, 8:340ra372.
[20] Amtul Z, Yang J, Nikolova S, Lee TY, Bartha R, Cechetto DF (2018). The Dynamics of Impaired Blood-Brain Barrier Restoration in a Rat Model of Co-morbid Injury. Mol Neurobiol, 55:8071-8083.
[21] Xu Z, Xiao N, Chen Y, Huang H, Marshall C, Gao J, et al. (2015). Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Abeta accumulation and memory deficits. Mol Neurodegener, 10:58.
[22] Liang R, Yong S, Huang X, Kong H, Hu G, Fan Y (2016). Aquaporin-4 Mediates the Suppressive Effect of Lipopolysaccharide on Hippocampal Neurogenesis. Neuroimmunomodulation, 23:309-317.
[23] Yang J, Zhang R, Shi C, Mao C, Yang Z, Suo Z, et al. (2017). AQP4 Association with Amyloid Deposition and Astrocyte Pathology in the Tg-ArcSwe Mouse Model of Alzheimer's Disease. J Alzheimers Dis, 57:157-169.
[24] Hoshi A, Tsunoda A, Yamamoto T, Tada M, Kakita A, Ugawa Y (2018). Altered expression of glutamate transporter-1 and water channel protein aquaporin-4 in human temporal cortex with Alzheimer's disease. Neuropathol Appl Neurobiol, 44:628-638.
[25] Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M (1988). Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology, 168:497-505.
[26] Xueying L, Zhongping Z, Zhoushe Z, Li G, Yongjin T, Changzheng S, et al. (2015). Investigation of Apparent Diffusion Coefficient from Ultra-high b-Values in Parkinson's Disease. Eur Radiol, 25:2593-2600.
[27] Tan Y, Zhang H, Wang XC, Qin JB, Wang L (2018). The value of multi ultra high-b-value DWI in grading cerebral astrocytomas and its association with aquaporin-4. Br J Radiol, 91:20170696. [in press].
[28] Yoshiura T, Mihara F, Tanaka A, Ogomori K, Ohyagi Y, Taniwaki T, et al. (2003). High b value diffusion-weighted imaging is more sensitive to white matter degeneration in Alzheimer's disease. Neuroimage, 20:413-419.
[29] Farrell JA, Zhang J, Jones MV, Deboy CA, Hoffman PN, Landman BA, et al. (2010). q-space and conventional diffusion imaging of axon and myelin damage in the rat spinal cord after axotomy. Magn Reson Med, 63:1323-1335.
[30] Jiang Q, Qu C, Chopp M, Ding GL, Davarani SP, Helpern JA, et al. (2011). MRI evaluation of axonal reorganization after bone marrow stromal cell treatment of traumatic brain injury. NMR Biomed, 24:1119-1128.
[31] Zhuo J, Xu S, Proctor JL, Mullins RJ, Simon JZ, Fiskum G, et al. (2012). Diffusion kurtosis as an in vivo imaging marker for reactive astrogliosis in traumatic brain injury. Neuroimage, 59:467-477.
[32] Yuan L, Sun M, Chen Y, Long M, Zhao X, Yin J, et al. (2016). Non-Gaussian diffusion alterations on diffusion kurtosis imaging in patients with early Alzheimer's disease. Neurosci Lett, 616:11-18.
[33] Rosenkrantz AB, Padhani AR, Chenevert TL, Koh DM, De Keyzer F, Taouli B, et al. (2015). Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice. J Magn Reson Imaging, 42:1190-1202.
[34] Gatidis S, Schmidt H, Martirosian P, Nikolaou K, Schwenzer NF (2016). Apparent diffusion coefficient-dependent voxelwise computed diffusion-weighted imaging: An approach for improving SNR and reducing T2 shine-through effects. J Magn Reson Imaging, 43:824-832.
[35] Kantarci K, Jack CRJr, Xu YC, Campeau NG, O'Brien PC, Smith GE, et al. (2001). Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology, 219:101-107.
[36] Englund E (1998). Neuropathology of white matter changes in Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord, 9 Suppl 1:6-12.
[37] Selkoe DJ (2000). Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci, 924:17-25.
[38] Yang J, Lunde LK, Nuntagij P, Oguchi T, Camassa LM, Nilsson LN, et al. (2011). Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer's disease. J Alzheimers Dis, 27:711-722.
[39] Yang C, Huang X, Huang X, Mai H, Li J, Jiang T, et al. (2016). Aquaporin-4 and Alzheimer's Disease. J Alzheimers Dis, 52:391-402.
[40] Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297:353-356.
[41] Whittaker HT, Zhu S, Di Curzio DL, Buist R, Li XM, Noy S, et al. (2018). T1, diffusion tensor, and quantitative magnetization transfer imaging of the hippocampus in an Alzheimer's disease mouse model. Magn Reson Imaging, 50:26-37.
[42] Rash JE, Yasumura T, Hudson CS, Agre P, Nielsen S (1998). Direct immunogold labeling of aquaporin-4 in square arrays of astrocyte and ependymocyte plasma membranes in rat brain and spinal cord. Proc Natl Acad Sci U S A, 95:11981-11986.
[43] Speake T, Freeman LJ, Brown PD (2003). Expression of aquaporin 1 and aquaporin 4 water channels in rat choroid plexus. Biochim Biophys Acta, 1609:80-86.
[44] Moftakhar P, Lynch MD, Pomakian JL, Vinters HV (2010). Aquaporin expression in the brains of patients with or without cerebral amyloid angiopathy. J Neuropathol Exp Neurol, 69:1201-1209.
[45] Zimny A, Bladowska J, Neska M, Petryszyn K, Guzinski M, Szewczyk P, et al. (2013). Quantitative MR evaluation of atrophy, as well as perfusion and diffusion alterations within hippocampi in patients with Alzheimer's disease and mild cognitive impairment. Med Sci Monit, 19:86-94.
[46] Struyfs H, Van Hecke W, Veraart J, Sijbers J, Slaets S, De Belder M, et al. (2015). Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis? J Alzheimers Dis, 48:937-948.
[47] Gong NJ, Chan CC, Leung LM, Wong CS, Dibb R, Liu C (2017). Differential microstructural and morphological abnormalities in mild cognitive impairment and Alzheimer's disease: Evidence from cortical and deep gray matter. Hum Brain Mapp, 38:2495-2508.
[48] Praet J, Manyakov NV, Muchene L, Mai Z, Terzopoulos V, de Backer S, et al. (2018). Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid-beta-induced pathology. Alzheimers Res Ther, 10:1.
[49] Vanhoutte G, Pereson S, Delgado YPR, Guns PJ, Asselbergh B, Veraart J, et al. (2013). Diffusion kurtosis imaging to detect amyloidosis in an APP/PS1 mouse model for Alzheimer's disease. Magn Reson Med, 69:1115-1121.
[50] Serot JM, Bene MC, Foliguet B, Faure GC (2000). Morphological alterations of the choroid plexus in late-onset Alzheimer's disease. Acta Neuropathol, 99:105-108.
[51] Serot JM, Bene MC, Faure GC (2003). Choroid plexus, aging of the brain, and Alzheimer's disease. Front Biosci, 8:s515-521.
[52] de Vos F, Koini M, Schouten TM, Seiler S, van der Grond J, Lechner A, et al. (2018). A comprehensive analysis of resting state fMRI measures to classify individual patients with Alzheimer's disease. Neuroimage, 167:62-72.
[53] Bouts M, Moller C, Hafkemeijer A, van Swieten JC, Dopper E, van der Flier WM, et al. (2018). Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. J Alzheimers Dis, 62:1827-1839.
[54] Jack CRJr, Wiste HJ, Knopman DS, Vemuri P, Mielke MM, Weigand SD, et al. (2014). Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology, 82:1605-1612.
[1] Xiao-Li Zhou, Meng-Bei Xu, Ting-Yu Jin, Pei-Qing Rong, Guo-Qing Zheng, Yan Lin. Preclinical Evidence and Possible Mechanisms of Extracts or Compounds from Cistanches for Alzheimer’s Disease[J]. Aging and disease, 2019, 10(5): 1075-1093.
[2] Zhi-Ying Tian, Chun-Yan Wang, Tao Wang, Yan-Chun Li, Zhan-You Wang. Glial S100A6 Degrades β-amyloid Aggregation through Targeting Competition with Zinc Ions[J]. Aging and disease, 2019, 10(4): 756-769.
[3] Takehiko Yamanaka, Yuto Uchida, Keita Sakurai, Daisuke Kato, Masayuki Mizuno, Toyohiro Sato, Yuta Madokoro, Yuko Kondo, Ayuko Suzuki, Yoshino Ueki, Fumiyasu Ishii, Cesar V Borlongan, Noriyuki Matsukawa. Anatomical Links between White Matter Hyperintensity and Medial Temporal Atrophy Reveal Impairment of Executive Functions[J]. Aging and disease, 2019, 10(4): 711-718.
[4] Yu-Sheng Li, Zhi-Hua Yang, Yao Zhang, Jing Yang, Dan-Dan Shang, Shu-Yu Zhang, Jun Wu, Yan Ji, Lu Zhao, Chang-He Shi, Yu-Ming Xu. Two Novel Mutations and a de novo Mutation in PSEN1 in Early-onset Alzheimer’s Disease[J]. Aging and disease, 2019, 10(4): 908-914.
[5] Qing-Qing Tao, Yu-Chao Chen, Zhi-Ying Wu. The role of CD2AP in the Pathogenesis of Alzheimer's Disease[J]. Aging and disease, 2019, 10(4): 901-907.
[6] Christopher Bi, Stephanie Bi, Bin Li. Processing of Mutant β-Amyloid Precursor Protein and the Clinicopathological Features of Familial Alzheimer’s Disease[J]. Aging and disease, 2019, 10(2): 383-403.
[7] Seong Gak Jeon, Eun Ji Song, Dongje Lee, Junyong Park, Yunkwon Nam, Jin-il Kim, Minho Moon. Traditional Oriental Medicines and Alzheimer’s Disease[J]. Aging and disease, 2019, 10(2): 307-328.
[8] Ashok K. Shetty, Raghavendra Upadhya, Leelavathi N. Madhu, Maheedhar Kodali. Novel Insights on Systemic and Brain Aging, Stroke, Amyotrophic Lateral Sclerosis, and Alzheimer’s Disease[J]. Aging and disease, 2019, 10(2): 470-482.
[9] Jong Bin Bae,Ji Won Han,Kyung Phil Kwak,Bong Jo Kim,Shin Gyeom Kim,Jeong Lan Kim,Tae Hui Kim,Seung-Ho Ryu,Seok Woo Moon,Joon Hyuk Park,Jong Chul Youn,Dong Young Lee,Dong Woo Lee,Seok Bum Lee,Jung Jae Lee,Jin Hyeong Jhoo,Ki Woong Kim. Is Dementia More Fatal Than Previously Estimated? A Population-based Prospective Cohort Study[J]. Aging and disease, 2019, 10(1): 1-11.
[10] Antonina Luca, Carmela Calandra, Maria Luca. Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia[J]. Aging and disease, 2018, 9(6): 1134-1152.
[11] Sone Daichi, Imabayashi Etsuko, Maikusa Norihide, Ogawa Masayo, Sato Noriko, Matsuda Hiroshi, Japanese-Alzheimer’s Disease Neuroimaging Initiative. Voxel-based Specific Regional Analysis System for Alzheimer’s Disease (VSRAD) on 3-tesla Normal Database: Diagnostic Accuracy in Two Independent Cohorts with Early Alzheimer’s Disease[J]. Aging and disease, 2018, 9(4): 755-760.
[12] Morroni Fabiana, Sita Giulia, Graziosi Agnese, Turrini Eleonora, Fimognari Carmela, Tarozzi Andrea, Hrelia Patrizia. Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer’s Disease Involves Nrf2/HO-1 Pathway[J]. Aging and disease, 2018, 9(4): 605-622.
[13] Xu Yangqi, Liu Xiaoli, Shen Junyi, Tian Wotu, Fang Rong, Li Binyin, Ma Jianfang, Cao Li, Chen Shengdi, Li Guanjun, Tang Huidong. The Whole Exome Sequencing Clarifies the Genotype- Phenotype Correlations in Patients with Early-Onset Dementia[J]. Aging and disease, 2018, 9(4): 696-705.
[14] Ding Qiong, Tanigawa Kitora, Kaneko Jun, Totsuka Mamoru, Katakura Yoshinori, Imabayashi Etsuko, Matsuda Hiroshi, Hisatsune Tatsuhiro. Anserine/Carnosine Supplementation Preserves Blood Flow in the Prefrontal Brain of Elderly People Carrying APOE e4[J]. Aging and disease, 2018, 9(3): 334-345.
[15] Shen Ting, You Yuyi, Joseph Chitra, Mirzaei Mehdi, Klistorner Alexander, Graham Stuart L., Gupta Vivek. BDNF Polymorphism: A Review of Its Diagnostic and Clinical Relevance in Neurodegenerative Disorders[J]. Aging and disease, 2018, 9(3): 523-536.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd